Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
This page provides a historical news archive for Cerevel Therapeutics Holdings, Inc. (formerly Nasdaq: CERE), a neuroscience-focused biopharmaceutical company that became part of AbbVie following the completion of an acquisition announced by AbbVie on August 1, 2024. Before the transaction, Cerevel regularly issued updates on its clinical pipeline, corporate strategy and capital raising activities.
News items for Cerevel include detailed announcements on its key investigational therapies such as emraclidine, tavapadon, darigabat, CVL-871 and CVL-354. These releases cover topics like Phase 2 and Phase 3 trial designs, topline clinical results, regulatory designations and development plans in schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, Parkinson’s disease, mood disorders and related neuroscience indications. For example, Cerevel announced positive topline results from the pivotal Phase 3 TEMPO-3 adjunctive trial of tavapadon in people living with Parkinson’s disease.
Investors and researchers can also review historical corporate and financial communications, including quarterly financial results, business updates, investor webcasts, and the October 2023 public offering of common stock that Cerevel stated would support operations and planned data readouts. In addition, the archive reflects transaction-related news, such as the December 6, 2023 joint announcement by AbbVie and Cerevel of a definitive acquisition agreement, and subsequent commentary from law firms examining the terms of the merger.
Although CERE shares are no longer expected to trade following the closing of the AbbVie acquisition, this news history remains useful for understanding how Cerevel’s neuroscience programs evolved, how management communicated clinical milestones, and how the acquisition rationale was framed by AbbVie. Users interested in ongoing development of these assets should consult AbbVie’s current disclosures, while using this page as a record of Cerevel’s standalone public-company era.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO, Tony Coles, M.D., will present at the 2023 BofA Securities Health Care Conference on May 10th at 10:00 am PT (1:00 pm ET). The presentation will be accessible via a live webcast on the investor relations section of the Cerevel website, with a replay available afterwards.
Cerevel focuses on treating neuroscience diseases by leveraging expertise in neurocircuitry and receptor subtype selectivity. The company has a diversified pipeline that includes five clinical-stage investigational therapies and preclinical compounds aimed at conditions such as schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson's disease.
Cerevel Therapeutics (Nasdaq: CERE) has announced it will report its first quarter 2023 financial results and business updates on May 3, 2023, before the U.S. markets open. A conference call to discuss these results is scheduled for the same day at 8:00 a.m. ET, which will be accessible via registration. Cerevel is focused on treating neuroscience diseases and has a diversified pipeline with five clinical-stage investigational therapies aimed at conditions such as schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. The company emphasizes its commitment to advancing research and development while exploring new avenues through collaborations or acquisitions. More details are available on their investor website.
Cerevel Therapeutics (Nasdaq: CERE) announced that its chairperson and CEO Tony Coles will participate in a fireside chat during the Stifel Virtual 2023 CNS Days on March 29, 2023, at 10:30 am ET. The event will highlight the company's ongoing commitment to neuroscience diseases and its diversified pipeline, which includes five clinical-stage investigational therapies aimed at conditions like schizophrenia, Alzheimer’s disease psychosis, and epilepsy. A live webcast of the presentation will be available on the investor relations section of Cerevel's website, with a replay accessible afterward.
FAQ
What is the current stock price of Cerevel Therapeutics Hldng (CERE)?
What is the market cap of Cerevel Therapeutics Hldng (CERE)?
